Aemetis (NASDAQ:AMTX – Free Report) had its price objective trimmed by UBS Group from $8.25 to $7.75 in a research note published on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the specialty chemicals company’s stock.
A number of other equities research analysts have also recently weighed in on the stock. HC Wainwright reissued a buy rating and issued a $28.00 price target on shares of Aemetis in a research report on Friday, August 2nd. Truist Financial reissued a hold rating and issued a $3.50 target price (down from $4.00) on shares of Aemetis in a report on Wednesday, July 31st. Finally, StockNews.com raised Aemetis to a sell rating in a research report on Wednesday, July 31st. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of Hold and an average target price of $11.44.
Read Our Latest Analysis on Aemetis
Aemetis Stock Performance
Aemetis (NASDAQ:AMTX – Get Free Report) last announced its quarterly earnings results on Thursday, August 1st. The specialty chemicals company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.25). The business had revenue of $66.56 million for the quarter, compared to the consensus estimate of $75.37 million. During the same quarter in the prior year, the company earned ($0.68) EPS. On average, sell-side analysts forecast that Aemetis will post -1.86 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new position in shares of Aemetis during the first quarter worth about $60,000. Hutchinson Capital Management CA purchased a new position in shares of Aemetis in the 2nd quarter valued at approximately $70,000. State Board of Administration of Florida Retirement System acquired a new position in shares of Aemetis in the first quarter valued at approximately $84,000. Rhumbline Advisers raised its stake in shares of Aemetis by 2,837.1% during the second quarter. Rhumbline Advisers now owns 52,309 shares of the specialty chemicals company’s stock worth $157,000 after purchasing an additional 50,528 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Aemetis during the second quarter worth $306,000. 27.02% of the stock is currently owned by institutional investors and hedge funds.
About Aemetis
Aemetis, Inc operates as a renewable natural gas and renewable fuels company. It operates through three segments: California Ethanol, California Dairy Renewable Natural Gas, and India Biodiesel. The company focuses on the operation, acquisition, development, and commercialization of technologies to produce low and negative carbon intensity renewable fuels that replace fossil-based products.
Recommended Stories
- Five stocks we like better than Aemetis
- What is a Bond Market Holiday? How to Invest and Trade
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- How to Buy Cheap Stocks Step by Step
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- What is a Stock Market Index and How Do You Use Them?
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Aemetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aemetis and related companies with MarketBeat.com's FREE daily email newsletter.